江苏澳肽信生物医药科技

Jiangsu Aotexin Biomedical Technology is a clinical-stage biotechnology company focused on the research and development of innovative peptide therapeutics. Founded in 2015 and based in Nanjing, China, the company collaborates closely with China Pharmaceutical University and Nanjing Anji Biotechnology to advance its pipeline. Its lead candidate is Pagantangentide (also known as pegylated antianji peptide), a pegylated recombinant peptide targeting integrin alpha-V/beta-3 (αvβ3) for the treatment of rheumatoid arthritis. The candidate is currently in Phase 1 clinical development in China. Jiangsu Aotexin leverages its expertise in peptide engineering to develop novel treatments for autoimmune and inflammatory diseases.